


**PRODUCT: Pexmetinib**

**ALTERNATE NAMES:** ARRY-614; ARRY614; ARRY 614; (Z)-N-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-N'-(5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)benzyl)carbamidic acid; 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[[5-fluoro-2-[1-(2-hydroxyethyl)indazol-5-yl]oxyphenyl]methyl]urea; 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)benzyl)urea

**CATALOG#:** B1711-5, -25

**AMOUNT:** 5 mg, 25 mg

**STRUCTURE:**



**MOLECULAR FORMULA:** C<sub>31</sub>H<sub>33</sub>FN<sub>6</sub>O<sub>3</sub>

**MOLECULAR WEIGHT:** 556.63

**CAS NUMBER:** 945614-12-0

**APPEARANCE:** Solid powder

**SOLUBILITY:** DMSO

**PURITY:** >98%

**STORAGE:** Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

**DESCRIPTION:** Pexmetinib (ARRY-614) is a potent inhibitor of cytokine synthesis, via the dual inhibition of p38 mitogen-activated protein kinase (MAPK), and Tie2/Tek receptor tyrosine kinase.

**REFERENCES:**

- Garcia-Manero G et al. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. *Clinical Cancer Research*, 2015, 21(5): 985-994.
- Wollenberg LA et al. An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614). *Clinical pharmacology: advances and applications*, 2015, 7: 87.

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**RELATED PRODUCTS:**

- Alsterpaullone (Cat. No. 1897-1, 5)
- AZD-6244 (Cat. No. 2234-5, 25)
- BIX01289 (Cat. No. 2670-1, 5)
- Butyrolactone I (Cat. No. 1690-200)
- Doramapimod (Cat. No. 1954-5, 25)
- Flavopiridol (Cat. No. 2090-1, 5)
- 10Z-Hymenialdisine (Cat. No. 2212-250, 1000)
- Kenpaullone (Cat. No. 1904-1)
- MEK-162 (Cat. No. 2254-5, 25)
- PD1834352 (CI-1040) (Cat. No. 1585-1, 5, 25)
- EZSolution™ PD1834352 (Cat. No. 1871-1)
- PD325901 (Cat. No. 1643-2, 5, 25)
- PD98059 (Cat. No. 1666-5)
- EZSolution™ PD98059 (Cat. No. 1783-5)
- RO-3306 (Cat. No. 2039-1, 5)
- Roscovitine (Cat. No. 1950-1, 5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB203580 (1786-1)
- SB202190 (Cat. No. 2493-5, 25)
- Sorafenib (Cat. No. 1594-25, 100)
- TAK733 (Cat. No. 2460-5, 25)
- TG003 (Cat. No. 1905-5, 25)
- 7, 3', 4'-Trihydroxyisoflavone (1886-25, 100)
- U0126 (Cat. No. 1668-5)
- VX-702 (Cat. No. 1598-1, 5)
- VX-745 (Cat. No. 2812-5, 25)

**USAGE:** **FOR RESEARCH USE ONLY! Not to be used in humans**